NCT03585023

Brief Summary

Correlation between the presence of intracellular viruses/bacteria and the incidence of miscarriage during the first trimester of pregnancy.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2014

Typical duration for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 15, 2014

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 15, 2016

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 14, 2017

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

June 4, 2018

Completed
1 month until next milestone

First Posted

Study publicly available on registry

July 12, 2018

Completed
Last Updated

July 12, 2018

Status Verified

June 1, 2018

Enrollment Period

2 years

First QC Date

June 4, 2018

Last Update Submit

June 30, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Individuation of DNA of intracellular agents (viral und bacterial) in chorionic tissue und blood sample.

    The primary outcome of this project is to find the DNA of viral (HPV, HPyV,BK and JC), or bacterial agents (Chlamydia trachomatis, Ureaplasma parvum, U. urealyticum, Mycoplasma hominis) in samples obtained from spontaneous abortion or elective interruption of pregnancy.

    December 2014 - April 2017

Study Arms (2)

Spontaneous miscarriage

The study group will be recruited at admission for uterine cavity revision planned for spontaneous abortion.

Diagnostic Test: Spontaneous miscarriageDiagnostic Test: Voluntary pregnancy interruption

Voluntary pregnancy interruption

The control group will be recruited at admission for uterine cavity revision planned for voluntary pregnancy interruption.

Diagnostic Test: Spontaneous miscarriageDiagnostic Test: Voluntary pregnancy interruption

Interventions

Viral DNA and RNA analysis of HPyV and HPV, BKV and JCV. Bacterial DNA and RNA analysis of Chlamydia trachomatis, Ureaplasma parvum, U. urealyticum, Mycoplasma hominis.

Spontaneous miscarriageVoluntary pregnancy interruption

Viral DNA and RNA analysis of HPyV and HPV, BKV and JCV. Bacterial DNA and RNA analysis of Chlamydia trachomatis, Ureaplasma parvum, U. urealyticum, Mycoplasma hominis.

Spontaneous miscarriageVoluntary pregnancy interruption

Eligibility Criteria

Age18 Years - 42 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility Detailswomen
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Women who underwent revision of uterine cavity for spontaneous abortion or voluntary termination of pregnancy

You may not qualify if:

  • age of the patients range from 18 to 42 years old;
  • gestational age ranging in the first 12 weeks.
  • medical history or laboratory tests positive for sexually transmitted diseases (HIV, HBV, HCV, LUE) during the last year;
  • Congenital or Acquired Immunodeficiency diseases, or immunosuppressive therapies during the last year;
  • Therapeutic abortion (voluntary interruption of pregnancy, law 194 art 6 comma b)
  • well known causes responsable for spontaneous abortions such as genetic, severe uterine or hormonal abnormalities and use of teratogenic drugs.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITH DNA

All samples, both spontaneous (spontaneous miscarriage) and elective (voluntary interruption of pregnancy), will be obtained after uterine cavity curettage. All women underwent PBMC extraction from peripheral whole blood.

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

June 4, 2018

First Posted

July 12, 2018

Study Start

November 15, 2014

Primary Completion

November 15, 2016

Study Completion

May 14, 2017

Last Updated

July 12, 2018

Record last verified: 2018-06